StemCells is steadily progressing its pipeline of proprietary human central nervous system stem cells (HuCNS-SC), focusing on CNS disorders. Trials in its two lead indications, spinal cord injuries (SCI) and dry age-related macular degeneration (AMD) are now migrating from early and encouraging dose finding and initial efficacy to larger Phase II studies powered for proof of concept. Early findings are expected to begin feeding through in the current year. We believe StemCells' shares offer c
08 Jun 2015
On the PATHWAY towards pivotal studies
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
On the PATHWAY towards pivotal studies
StemCells is steadily progressing its pipeline of proprietary human central nervous system stem cells (HuCNS-SC), focusing on CNS disorders. Trials in its two lead indications, spinal cord injuries (SCI) and dry age-related macular degeneration (AMD) are now migrating from early and encouraging dose finding and initial efficacy to larger Phase II studies powered for proof of concept. Early findings are expected to begin feeding through in the current year. We believe StemCells' shares offer c